These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8058688)

  • 1. [Use of glurenorm in patients with non-insulin-dependent diabetes mellitus and liver diseases].
    Dedov II; Demidova IIu; Pisklakov SV; Antokhin EA
    Probl Endokrinol (Mosk); 1993; 39(3):6-8. PubMed ID: 8058688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glurenorm in the treatment of patients with non-insulin-dependent diabetes mellitus with diseases of the liver and bile ducts].
    Balabolkin MI; Nedosugova LV
    Probl Endokrinol (Mosk); 1993; 39(4):16-8. PubMed ID: 8415521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of glurenorm on plasma glucose and lipids in patients with type 2 diabetes mellitus.
    Chou SC; Chen KW; Huang CC; Lin KD; Hwang JS; Lin JD
    Chang Gung Med J; 2000 Aug; 23(8):480-4. PubMed ID: 11039250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
    Dills DG; Schneider J
    Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of non-insulin-dependent diabetes mellitus.
    Davidson MB
    Mayo Clin Proc; 1997 Jan; 72(1):92. PubMed ID: 9005295
    [No Abstract]   [Full Text] [Related]  

  • 7. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.
    Kobayashi T; Nakanishi K; Murase T; Kosaka K
    Diabetes; 1996 May; 45(5):622-6. PubMed ID: 8621013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.
    Ravnik-Oblak M; Mrevlje F
    Diabetes Res Clin Pract; 1995 Oct; 30(1):27-35. PubMed ID: 8745203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 10. [A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus].
    Kakhnovskiĭ IM; Koroleva TV; Zakharchenko VN; Larionov SN
    Probl Endokrinol (Mosk); 1993; 39(2):7-9. PubMed ID: 8016059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined therapy with insulin/gliquidone (Glurenorm) in type 2 diabetes after treatment failure using oral antidiabetic agents].
    Podrouzková B; Krusová D
    Vnitr Lek; 1992 Oct; 38(10):963-7. PubMed ID: 1481374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effectiveness of combined insulin and sulfonylurea in treating non-insulin dependent diabetic patients].
    Sun Y; Xiong Y; Yang J
    Zhonghua Nei Ke Za Zhi; 1995 Apr; 34(4):246-9. PubMed ID: 7587604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of sugar-reducing therapy on renal function in patients with type II diabetes mellitus].
    Mazurov VI; Novik AA; Nagibovich OA; Romashevskiĭ BV; Guliaeva IV; Kurganova TA
    Klin Med (Mosk); 1998; 76(6):38-41. PubMed ID: 9693499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experience with Glurenorm in type 2 diabetics with renal insufficiency].
    Rybka J; Gregorová A; Zmydlená A
    Vnitr Lek; 1988 Aug; 34(8):786-92. PubMed ID: 3176368
    [No Abstract]   [Full Text] [Related]  

  • 16. [The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus].
    Degtiareva II; Lodianaia EV; Opanasiuk ND; Palladina OL
    Lik Sprava; 1995; (7-8):84-7. PubMed ID: 8846383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus.
    Riddle MC
    Diabetes Res Clin Pract; 1991 Jan; 11(1):3-8. PubMed ID: 2019232
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
    Osei K; Falko JM
    Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Rosenstock J; Samols E; Muchmore DB; Schneider J
    Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.